Adhera Therapeutics, Inc. (ATRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 22.26 Million USD | -12.0% |
| 2021 | 25.3 Million USD | 71.26% |
| 2020 | 14.77 Million USD | 43.34% |
| 2019 | 10.3 Million USD | 365.51% |
| 2018 | 2.21 Million USD | -61.4% |
| 2017 | 5.73 Million USD | 93.27% |
| 2016 | 2.96 Million USD | -59.52% |
| 2015 | 7.33 Million USD | -46.04% |
| 2014 | 13.58 Million USD | -8.23% |
| 2013 | 14.8 Million USD | 13.19% |
| 2012 | 13.08 Million USD | 11.69% |
| 2011 | 11.71 Million USD | -4.58% |
| 2010 | 12.27 Million USD | -13.04% |
| 2009 | 14.11 Million USD | -13.91% |
| 2008 | 16.39 Million USD | -26.79% |
| 2007 | 22.39 Million USD | -26.56% |
| 2006 | 30.49 Million USD | 75.41% |
| 2005 | 17.38 Million USD | -23.16% |
| 2004 | 22.62 Million USD | 71.0% |
| 2003 | 13.23 Million USD | -8.14% |
| 2002 | 14.4 Million USD | 640.24% |
| 2001 | 1.94 Million USD | -7.16% |
| 2000 | 2.09 Million USD | -41.78% |
| 1999 | 3.6 Million USD | 80.0% |
| 1998 | 2 Million USD | -20.0% |
| 1997 | 2.5 Million USD | 127.27% |
| 1996 | 1.1 Million USD | -38.89% |
| 1995 | 1.8 Million USD | 5.88% |
| 1994 | 1.7 Million USD | 8.97% |
| 1993 | 1.56 Million USD | -12.85% |
| 1992 | 1.79 Million USD | 3.47% |
| 1991 | 1.73 Million USD | 37.3% |
| 1990 | 1.26 Million USD | 29.9% |
| 1989 | 970 Thousand USD | 203.13% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 23.19 Million USD | 4.19% |
| 2023 Q3 | 26.35 Million USD | 15.26% |
| 2023 Q2 | 22.86 Million USD | -1.41% |
| 2022 Q1 | 25.66 Million USD | 1.45% |
| 2022 Q3 | 22.06 Million USD | 5.21% |
| 2022 FY | 22.26 Million USD | -12.0% |
| 2022 Q2 | 20.97 Million USD | -18.3% |
| 2022 Q4 | 22.26 Million USD | 0.92% |
| 2021 Q1 | 15.5 Million USD | 4.95% |
| 2021 Q3 | 20.39 Million USD | 24.47% |
| 2021 Q4 | 25.3 Million USD | 24.09% |
| 2021 FY | 25.3 Million USD | 71.26% |
| 2021 Q2 | 16.38 Million USD | 5.65% |
| 2020 FY | 14.77 Million USD | 43.34% |
| 2020 Q1 | 12.14 Million USD | 17.86% |
| 2020 Q2 | 13.24 Million USD | 9.06% |
| 2020 Q3 | 14.08 Million USD | 6.27% |
| 2020 Q4 | 14.77 Million USD | 4.93% |
| 2019 Q2 | 5.26 Million USD | 82.45% |
| 2019 FY | 10.3 Million USD | 365.51% |
| 2019 Q1 | 2.88 Million USD | 30.38% |
| 2019 Q4 | 10.3 Million USD | 8.27% |
| 2019 Q3 | 9.52 Million USD | 80.75% |
| 2018 FY | 2.21 Million USD | -61.4% |
| 2018 Q2 | 2.33 Million USD | -66.01% |
| 2018 Q1 | 6.87 Million USD | 19.89% |
| 2018 Q3 | 2.18 Million USD | -6.51% |
| 2018 Q4 | 2.21 Million USD | 1.32% |
| 2017 Q2 | 4.15 Million USD | 54.1% |
| 2017 Q1 | 2.69 Million USD | -9.06% |
| 2017 Q4 | 5.73 Million USD | 24.29% |
| 2017 Q3 | 4.61 Million USD | 10.96% |
| 2017 FY | 5.73 Million USD | 93.27% |
| 2016 Q1 | 5.69 Million USD | -22.37% |
| 2016 Q2 | 6.07 Million USD | 6.66% |
| 2016 Q3 | 5.47 Million USD | -9.78% |
| 2016 Q4 | 2.96 Million USD | -45.82% |
| 2016 FY | 2.96 Million USD | -59.52% |
| 2015 Q2 | 10.04 Million USD | -14.1% |
| 2015 Q3 | 8.52 Million USD | -15.19% |
| 2015 Q4 | 7.33 Million USD | -13.97% |
| 2015 Q1 | 11.69 Million USD | -13.9% |
| 2015 FY | 7.33 Million USD | -46.04% |
| 2014 Q2 | 14.43 Million USD | -26.58% |
| 2014 Q4 | 13.58 Million USD | -32.55% |
| 2014 FY | 13.58 Million USD | -8.23% |
| 2014 Q1 | 19.65 Million USD | 32.74% |
| 2014 Q3 | 20.14 Million USD | 39.6% |
| 2013 FY | 14.8 Million USD | 13.19% |
| 2013 Q4 | 14.8 Million USD | 20.28% |
| 2013 Q3 | 12.31 Million USD | 11.3% |
| 2013 Q2 | 11.06 Million USD | -0.51% |
| 2013 Q1 | 11.11 Million USD | -15.01% |
| 2012 Q1 | 14.01 Million USD | 19.67% |
| 2012 Q2 | 12.03 Million USD | -14.13% |
| 2012 FY | 13.08 Million USD | 11.69% |
| 2012 Q3 | 10.36 Million USD | -13.9% |
| 2012 Q4 | 13.08 Million USD | 26.23% |
| 2011 Q3 | 12.26 Million USD | -22.83% |
| 2011 Q1 | 9.84 Million USD | -19.81% |
| 2011 FY | 11.71 Million USD | -4.58% |
| 2011 Q2 | 15.88 Million USD | 61.43% |
| 2011 Q4 | 11.71 Million USD | -4.47% |
| 2010 Q1 | 18.12 Million USD | 28.37% |
| 2010 FY | 12.27 Million USD | -13.04% |
| 2010 Q4 | 12.27 Million USD | -13.04% |
| 2010 Q3 | 14.11 Million USD | -28.74% |
| 2010 Q2 | 19.8 Million USD | 9.32% |
| 2009 FY | 14.11 Million USD | -13.91% |
| 2009 Q1 | 11.25 Million USD | -31.35% |
| 2009 Q2 | 16.68 Million USD | 48.26% |
| 2009 Q3 | 16.61 Million USD | -0.45% |
| 2009 Q4 | 14.11 Million USD | -15.04% |
| 2008 Q1 | 19.34 Million USD | -13.63% |
| 2008 Q4 | 16.39 Million USD | 2.87% |
| 2008 FY | 16.39 Million USD | -26.79% |
| 2008 Q3 | 15.93 Million USD | 0.08% |
| 2008 Q2 | 15.92 Million USD | -17.67% |
| 2007 Q1 | 28.77 Million USD | -5.64% |
| 2007 Q2 | 28.25 Million USD | -1.81% |
| 2007 Q3 | 28.67 Million USD | 1.49% |
| 2007 Q4 | 22.39 Million USD | -21.9% |
| 2007 FY | 22.39 Million USD | -26.56% |
| 2006 Q1 | 21.86 Million USD | 25.77% |
| 2006 Q4 | 30.49 Million USD | 16.62% |
| 2006 FY | 30.49 Million USD | 75.41% |
| 2006 Q2 | 23.35 Million USD | 6.81% |
| 2006 Q3 | 26.14 Million USD | 11.96% |
| 2005 Q4 | 17.38 Million USD | 14.08% |
| 2005 FY | 17.38 Million USD | -23.16% |
| 2005 Q3 | 15.24 Million USD | -6.19% |
| 2005 Q2 | 16.24 Million USD | 12.27% |
| 2005 Q1 | 14.47 Million USD | -36.05% |
| 2004 FY | 22.62 Million USD | 71.0% |
| 2004 Q4 | 22.62 Million USD | 9.19% |
| 2004 Q3 | 20.72 Million USD | 33.62% |
| 2004 Q2 | 15.5 Million USD | 4.45% |
| 2004 Q1 | 14.84 Million USD | 12.21% |
| 2003 Q1 | 25.05 Million USD | 73.93% |
| 2003 Q2 | 13.91 Million USD | -44.46% |
| 2003 FY | 13.23 Million USD | -8.14% |
| 2003 Q4 | 13.23 Million USD | -2.58% |
| 2003 Q3 | 13.58 Million USD | -2.39% |
| 2002 Q3 | 14.84 Million USD | 90.43% |
| 2002 Q2 | 7.79 Million USD | 44.01% |
| 2002 Q1 | 5.41 Million USD | 178.11% |
| 2002 FY | 14.4 Million USD | 640.24% |
| 2002 Q4 | 14.4 Million USD | -2.94% |
| 2001 Q2 | 1.86 Million USD | -15.07% |
| 2001 FY | 1.94 Million USD | -7.16% |
| 2001 Q4 | 1.94 Million USD | 8.59% |
| 2001 Q3 | 1.79 Million USD | -3.97% |
| 2001 Q1 | 2.19 Million USD | 4.82% |
| 2000 Q3 | 2.38 Million USD | -0.04% |
| 2000 Q1 | 1.89 Million USD | -47.42% |
| 2000 FY | 2.09 Million USD | -41.78% |
| 2000 Q4 | 2.09 Million USD | -12.23% |
| 2000 Q2 | 2.38 Million USD | 26.2% |
| 1999 Q2 | 2 Million USD | -13.04% |
| 1999 FY | 3.6 Million USD | 80.0% |
| 1999 Q3 | 2.6 Million USD | 30.0% |
| 1999 Q4 | 3.6 Million USD | 38.46% |
| 1999 Q1 | 2.3 Million USD | 15.0% |
| 1998 FY | 2 Million USD | -20.0% |
| 1998 Q3 | 2.1 Million USD | 0.0% |
| 1998 Q4 | 2 Million USD | -4.76% |
| 1998 Q2 | 2.1 Million USD | 23.53% |
| 1998 Q1 | 1.7 Million USD | -32.0% |
| 1997 Q4 | 2.5 Million USD | 31.58% |
| 1997 Q3 | 1.9 Million USD | 5.56% |
| 1997 Q2 | 1.8 Million USD | 28.57% |
| 1997 Q1 | 1.4 Million USD | 0.0% |
| 1997 FY | 2.5 Million USD | 127.27% |
| 1996 Q2 | 1.8 Million USD | 20.0% |
| 1996 Q1 | 1.5 Million USD | 0.0% |
| 1996 FY | 1.1 Million USD | -38.89% |
| 1996 Q3 | 800 Thousand USD | -55.56% |
| 1995 Q3 | 1.7 Million USD | -5.56% |
| 1995 FY | 1.8 Million USD | 5.88% |
| 1995 Q1 | 1.5 Million USD | 7.14% |
| 1995 Q2 | 1.8 Million USD | 20.0% |
| 1995 Q4 | 1.5 Million USD | -11.76% |
| 1994 Q4 | 1.4 Million USD | -6.67% |
| 1994 FY | 1.7 Million USD | 8.97% |
| 1994 Q1 | 1.5 Million USD | -6.25% |
| 1994 Q2 | 1.7 Million USD | 13.33% |
| 1994 Q3 | 1.5 Million USD | -11.76% |
| 1993 FY | 1.56 Million USD | -12.85% |
| 1993 Q4 | 1.6 Million USD | 0.0% |
| 1993 Q3 | 1.6 Million USD | 0.0% |
| 1992 FY | 1.79 Million USD | 3.47% |
| 1991 FY | 1.73 Million USD | 37.3% |
| 1990 FY | 1.26 Million USD | 29.9% |
| 1989 FY | 970 Thousand USD | 203.13% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -81061.375% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -135.212% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 69.277% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -2652.864% |
| Rebus Holdings, Inc. | 5.24 Million USD | -324.742% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 62.272% |
| Qrons Inc. | 1.48 Million USD | -1395.587% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -1715.753% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 70.282% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -49714.301% |
| Skye Bioscience, Inc. | 14.07 Million USD | -58.219% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 58.231% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -132.362% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -5181.473% |
| SQZ Biotechnologies Company | 50.03 Million USD | 55.505% |
| Intellipharmaceutics International Inc. | 12 Million USD | -85.406% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -478.098% |
| Mesoblast Limited | 188.44 Million USD | 88.185% |
| Marizyme, Inc. | 26.67 Million USD | 16.535% |
| Genus plc | 485 Million USD | 95.409% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -281.079% |
| Pharming Group N.V. | 244.07 Million USD | 90.878% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1007.64% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -784.821% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -485.921% |
| ContraFect Corporation | 32.53 Million USD | 31.558% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1023.753% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -481.689% |
| IMV Inc. | 37.93 Million USD | 41.304% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -89.036% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1376262.299% |
| ONE Bio Corp. | 27.49 Million USD | 19.024% |
| Accustem Sciences Inc. | 1.07 Million USD | -1963.028% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 71.24% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -952.684% |
| Q BioMed Inc. | 8.13 Million USD | -173.763% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 73.154% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -332.663% |
| Biomind Labs Inc. | 1.49 Million USD | -1385.708% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 81.246% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -146.234% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -20.983% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1452.8% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -15569.095% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -10970.725% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -287.499% |
| GB Sciences, Inc. | 5.41 Million USD | -310.979% |
| Alpha Cognition Inc. | 7.16 Million USD | -210.756% |
| HST Global, Inc. | 593.59 Thousand USD | -3650.887% |
| CSL Limited | 18.62 Billion USD | 99.88% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1668.196% |
| Halberd Corporation | 728.71 Thousand USD | -2955.362% |
| Enzolytics Inc. | 365.26 Million USD | 93.904% |
| Agentix Corp. | 2.51 Million USD | -786.856% |
| Resverlogix Corp. | 67.39 Million USD | 66.964% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2554.602% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 94.996% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1199.008% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 10.026% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -87.052% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -507.476% |
| AVAX Technologies, Inc. | 3.99 Million USD | -457.497% |
| Zenith Capital Corp. | 27.56 Thousand USD | -80661.0% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.321% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -9229.406% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -496.229% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -3170.254% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -721.09% |
| Kadimastem Ltd | 3.5 Million USD | -535.259% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -33166.596% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 55.704% |
| BioStem Technologies, Inc. | 15.9 Million USD | -39.99% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -4691.273% |
| LadRx Corporation | 2.2 Million USD | -911.803% |
| Cell Source, Inc. | 15.8 Million USD | -40.858% |
| Regen BioPharma, Inc. | 5.45 Million USD | -307.962% |
| Regen BioPharma, Inc. | 5.45 Million USD | -307.962% |
| NovAccess Global Inc. | 7.86 Million USD | -183.243% |
| Affymax, Inc. | 8.87 Million USD | -150.986% |
| Itoco Inc. | 1.65 Million USD | -1246.822% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -985.269% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -268.077% |
| Mobile Lads Corp. | 1.31 Million USD | -1595.093% |
| CytoDyn Inc. | 127.89 Million USD | 82.591% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -53166.825% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1321.433% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -101.579% |
| SYBLEU INC | 681.41 Thousand USD | -3167.475% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -264.886% |
| International Stem Cell Corporation | 5.27 Million USD | -321.925% |
| Bioxytran, Inc. | 3.24 Million USD | -585.182% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -3457.795% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -382.226% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 45.69% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -999.296% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -306.444% |
| Neutra Corp. | 973.52 Thousand USD | -2187.04% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 23.264% |
| PureTech Health plc | 125.58 Million USD | 82.271% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -492.607% |
| IXICO plc | 1.9 Million USD | -1071.662% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -8.456% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 78.451% |
| CSL Limited | 18.62 Billion USD | 99.88% |
| Cellectis S.A. | 249.36 Million USD | 91.071% |